文献速递胸部肿瘤

Telisotuzumab Vedotin靶向c-Met抗体药物偶联物首次人体I期剂量递增和扩展研究

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
PubMed 文献 · J Clin Oncol · 2018-10-04

该首次人体I期研究评估了靶向c-Met的抗体药物偶联物Teliso-V在晚期实体瘤患者中的安全性、耐受性、药代动力学和最大耐受剂量,并确定II期推荐剂量为2.7 mg/kg。在c-Met阳性非小细胞肺癌患者中观察到初步抗肿瘤活性,部分缓解率为18.8%。

要点

  • Teliso-V在晚期实体瘤中安全性可耐受,II期推荐剂量为2.7 mg/kg。
  • c-Met阳性NSCLC患者中部分缓解率为18.8%,中位缓解持续时间4.8个月。
  • 常见不良事件包括疲劳、恶心、便秘等,≥3级相关事件少见。

核心结论

  • Teliso-V单药治疗表现出良好的安全性和耐受性,并在c-Met阳性非小细胞肺癌患者中显示出令人鼓舞的抗肿瘤活性证据。

研究设计与样本

  • 首次人体I期剂量递增和扩展研究,剂量递增阶段纳入晚期实体瘤患者,扩展阶段纳入c-Met过表达的非小细胞肺癌患者。
  • Teliso-V静脉给药,每3周一次,第1天给药。

主要发现

  • 3.0 mg/kg队列(n=9)和3.3 mg/kg队列(n=3)各有一例患者出现剂量限制性毒性。
  • 未正式确定最大耐受剂量,基于总体安全性和耐受性将II期推荐剂量定为2.7 mg/kg。
  • 最常见任何级别治疗中出现的不良事件为疲劳(42%)、恶心(27%)、便秘(27%)、食欲下降(23%)、呕吐(21%)、呼吸困难(21%)、腹泻(19%)、外周水肿(19%)和神经病变(17%)。
  • 最常见的Teliso-V相关≥3级不良事件为疲劳、贫血、中性粒细胞减少和低白蛋白血症(各4%)。
  • Teliso-V和总抗体的药代动力学大致呈剂量比例,平均调和半衰期各为2至4天。

关键数值与推荐

  • 前瞻性筛查发现58例非小细胞肺癌患者中35例(60%)为c-Met阳性。
  • 16例c-Met阳性非小细胞肺癌患者接受Teliso-V 2.4至3.0 mg/kg治疗,其中3例(18.8%;95% CI,4.1%至45.7%)达到部分缓解。
  • 中位缓解持续时间为4.8个月;中位无进展生存期为5.7个月(95% CI,1.2个月至15.4个月)。
  • c-Met阳性定义为免疫组化膜H评分≥150。

临床怎么用

  • Teliso-V在c-Met阳性非小细胞肺癌患者中显示出初步疗效,II期推荐剂量为2.7 mg/kg每3周一次。
  • 治疗期间需监测疲劳、恶心、便秘等常见不良事件及≥3级血液学毒性。
  • c-Met过表达的非小细胞肺癌患者可能从Teliso-V治疗中获益。

局限性

  • 研究为I期剂量递增和扩展研究,样本量较小。
  • 未正式确定最大耐受剂量。
  • 疗效数据仅限于c-Met阳性非小细胞肺癌亚组,其他肿瘤类型未观察到缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. MATERIALS AND METHODS: For dose escalation, three to six patients with advanced solid tumors were enrolled in eight cohorts (0.15 to 3.3 mg/kg). The dose-expansion phase enrolled patients with non-small-cell lung cancer (NSCLC) with c-Met-overexpressing tumors (c-Met positive; immunohistochemistry membrane H-score ≥ 150). Patients received Teliso-V monotherapy intravenously on day 1 once every 3 weeks. Safety, tolerability, pharmacokinetics, and maximum tolerated dose were determined. RESULTS: Forty-eight patients were enrolled (median age, 65 years; 35.4% NSCLC; median four prior therapies). One patient each in the 3.0-mg/kg (n = 9) and 3.3-mg/kg (n = 3) cohorts experienced dose-limiting toxicities. Although the maximum tolerated dose was not formally identified, the recommended phase II dose was defined as 2.7 mg/kg on the basis of overall safety and tolerability. The most frequent treatment-emergent adverse events (any grade) were fatigue (42%), nausea (27%), constipation (27%), decreased appetite (23%), vomiting (21%), dyspnea (21%), diarrhea (19%), peripheral edema (19%), and neuropathy (17%). The most frequent Teliso-V-related grade ≥ 3 adverse events were fatigue, anemia, neutropenia, and hypoalbuminemia (4% each). Teliso-V and total antibody pharmacokinetics were approximately dose proportional, with a mean harmonic half-life of 2 to 4 days each. Prospective screening identified 35 (60%) of 58 patients with c-Met-positive NSCLC. Of 16 patients with c-Met-positive NSCLC who were treated with Teliso-V 2.4 to 3.0 mg/kg, three (18.8%; 95% CI, 4.1% to 45.7%) achieved a partial response (median response duration, 4.8 months; median progression-free survival, 5.7 months; 95% CI, 1.2 months to 15.4 months). No other patients experienced a response. CONCLUSION: Teliso-V monotherapy demonstrated favorable safety and tolerability profiles, with encouraging evidence of antitumor activity in patients with c-Met-positive NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Strickler JH, Weekes CD, Nemunaitis J, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018. PMID: 30285518. doi:10.1200/JCO.2018.78.7697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。